What is BIO's health score?

BIO-RAD LABORATORIES, INC. (BIO) has a TradeApes health score of 49 out of 100, rated Mixed. This composite score evaluates financial strength, operating trends, valuation, capital allocation, and risk factors.

What is BIO's estimated fair value?

Based on our 5-year discounted cash flow model, BIO-RAD LABORATORIES, INC.'s estimated fair value is $51.76 per share, representing a -82.4% downside from the current price. This is a model estimate, not a price target or investment recommendation.

Is BIO undervalued or overvalued?

Our model currently rates BIO as Overvalued. This assessment combines health metrics, valuation multiples, and market sentiment. Individual investors should conduct their own due diligence.

Crunching the numbers for BIO... Refresh in a moment for the full analysis.

BIO-RAD LABORATORIES, INC. (BIO)

Healthcare Overvalued low mixed

$294.32

Updated: 2026-06-06

TradeApes Score

Financial Strength

50 Mixed

Operating Trend

58 Mixed

Relative Value

10 Stressed

Capital Allocation

80 Strong

Risk

70 Healthy

Est. Fair Value $51.76

DCF Upside -82.4%

Sector Rank #996 of 6852

Key Findings

+ Free cash flow positive — business generates real spendable cash

Unlock Full Report →

− Historically expensive — EV/EBITDA in top 20% of its 5-year range

Unlock Full Report →

3 free score cards remaining

TradeApes provides financial data, analytics, and research tools. TradeApes is not a registered investment adviser, broker-dealer, or tax advisor. The information presented is for educational and informational purposes only and does not constitute investment, financial, or tax advice.

11 sector-leading stocks delivered to your inbox every Sunday. Free.

No spam. Unsubscribe anytime.